Redalpine

Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, founded in 2019. The company specializes in developing antibody-drug conjugate (ADC) linker technology aimed at enhancing chemotherapy by delivering chemotherapeutic agents directly to targeted antibodies. This innovative platform allows for the rapid production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines, enabling the use of readily available antibodies. The site-specific conjugation process facilitates swift manufacturing and reliable quality control, supporting the creation of safe and potent drugs for various diseases. Araris Biotech's technology is protected by two patents, underscoring its commitment to advancing cancer treatment through improved safety and tolerability for patients.

Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, founded in 2019. The company specializes in developing antibody-drug conjugate (ADC) linker technology aimed at enhancing chemotherapy by delivering chemotherapeutic agents directly to targeted antibodies. This innovative platform allows for the rapid production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines, enabling the use of readily available antibodies. The site-specific conjugation process facilitates swift manufacturing and reliable quality control, supporting the creation of safe and potent drugs for various diseases. Araris Biotech's technology is protected by two patents, underscoring its commitment to advancing cancer treatment through improved safety and tolerability for patients.

Versantis AG is a Swiss pharmaceutical company focused on developing innovative medicines and diagnostics for liver diseases. Founded in 2015 and based in Zurich, Versantis aims to address significant unmet medical needs for patients globally. Its lead candidate, VS-01, is currently in preclinical development and has the potential to be the first treatment for acute liver disease while simultaneously supporting multiple failing organs. VS-01 has received Orphan Drug Designation for its application in acute liver failure. The company also has additional treatments in its pipeline, including VS-02 and VS-03, which target chronic liver diseases and drug intoxications, respectively. These developments represent substantial market opportunities and underscore Versantis' commitment to improving patient outcomes for millions affected by liver conditions and related disorders.

Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, founded in 2019. The company specializes in developing antibody-drug conjugate (ADC) linker technology aimed at enhancing chemotherapy by delivering chemotherapeutic agents directly to targeted antibodies. This innovative platform allows for the rapid production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines, enabling the use of readily available antibodies. The site-specific conjugation process facilitates swift manufacturing and reliable quality control, supporting the creation of safe and potent drugs for various diseases. Araris Biotech's technology is protected by two patents, underscoring its commitment to advancing cancer treatment through improved safety and tolerability for patients.

RosieReality is a company based in Zurich, Switzerland, founded in 2017, that specializes in developing an educational mobile application named Rosie. Aimed at children aged 9 and up, the app utilizes augmented reality to create an engaging learning experience focused on science and basic robotics coding. Through the interactive platform, users can program Rosie the Robot using magical 3D shapes to solve AR puzzles and complete various challenges. This gamified approach not only fosters curiosity in scientific exploration but also offers parents a fun and educational tool to support their children's learning in technology and coding.

Versantis AG is a Swiss pharmaceutical company focused on developing innovative medicines and diagnostics for liver diseases. Founded in 2015 and based in Zurich, Versantis aims to address significant unmet medical needs for patients globally. Its lead candidate, VS-01, is currently in preclinical development and has the potential to be the first treatment for acute liver disease while simultaneously supporting multiple failing organs. VS-01 has received Orphan Drug Designation for its application in acute liver failure. The company also has additional treatments in its pipeline, including VS-02 and VS-03, which target chronic liver diseases and drug intoxications, respectively. These developments represent substantial market opportunities and underscore Versantis' commitment to improving patient outcomes for millions affected by liver conditions and related disorders.

Bexio AG is a Swiss company that specializes in providing cloud-based business and accounting software tailored for small and medium-sized enterprises. Founded in 2013 and based in Rapperswil, the company was previously known as easySYS AG before rebranding in 2015. Bexio AG focuses on simplifying accounting processes and enhancing business management through its user-friendly platform, which employs a standardized interface to facilitate interactions between businesses and their trustees, banks, and service providers. As of mid-2018, Bexio operates as a subsidiary of Schweizerische Mobiliar Versicherungsgesellschaft AG, reflecting its commitment to supporting the growth and efficiency of small businesses in Switzerland.

Founded in 2013 by Dennis Just and Christina Kehl, Knip is a technology company specializing in insurance management. Headquartered in Zurich with offices in Berlin and Belgrade, the company employs over 100 individuals. Knip's flagship product is an innovative mobile application that enables users to track their insurance policies, premiums, and benefits. The platform offers electronic adjustment of premiums, execution of new policies, cancellation of old ones, and unbiased advice from insurance experts.

Bexio AG is a Swiss company that specializes in providing cloud-based business and accounting software tailored for small and medium-sized enterprises. Founded in 2013 and based in Rapperswil, the company was previously known as easySYS AG before rebranding in 2015. Bexio AG focuses on simplifying accounting processes and enhancing business management through its user-friendly platform, which employs a standardized interface to facilitate interactions between businesses and their trustees, banks, and service providers. As of mid-2018, Bexio operates as a subsidiary of Schweizerische Mobiliar Versicherungsgesellschaft AG, reflecting its commitment to supporting the growth and efficiency of small businesses in Switzerland.

Founded in 2006 as an ETH Zurich spin-off, Redbiotec is a biotech company based in Zurich-Schlieren. Initially known for its vaccine innovations, it sold its CMV vaccine business to Pfizer and developed an HSV-2 immunotherapy. Currently, the company focuses on developing bacteria-based gene therapies to treat cancer and genetic disorders using its proprietary platform designed to overcome delivery challenges.

Founded in 2013 by Dennis Just and Christina Kehl, Knip is a technology company specializing in insurance management. Headquartered in Zurich with offices in Berlin and Belgrade, the company employs over 100 individuals. Knip's flagship product is an innovative mobile application that enables users to track their insurance policies, premiums, and benefits. The platform offers electronic adjustment of premiums, execution of new policies, cancellation of old ones, and unbiased advice from insurance experts.

Redvax is a spin-off from Redbiotec AG, a privately held Swiss biopharmaceutical company, based in Zurich-Schlieren. Redvax is a preclinical stage company. The company develops multi-component virus-like particles (VLPs) and other protein assemblies for vaccine development in the field of CMV and a further undisclosed field.